# Milestone Scientific Inc.: Form 10-Q for the period ended Jun 30, 2021

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2021-08-13
- Accepted by EDGAR: Aug 13, 2021, 16:19 ET
- Period: 2021-06-30
- Accession: 0001437749-21-019885
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000143774921019885/mlss20210630_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000143774921019885/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-04-01 to 2021-06-30 | $2.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months, 2021-01-01 to 2021-06-30 | $5.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2021-04-01 to 2021-06-30 | $1.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2021-01-01 to 2021-06-30 | $2.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2021-04-01 to 2021-06-30 | $1.4m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2021-01-01 to 2021-06-30 | $3.2m | us-gaap:GrossProfit |
| Research and development | 3 months, 2021-04-01 to 2021-06-30 | $14.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2021-01-01 to 2021-06-30 | $35.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-04-01 to 2021-06-30 | $4.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2021-01-01 to 2021-06-30 | $6.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-04-01 to 2021-06-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2021-01-01 to 2021-06-30 | −$3.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2021-04-01 to 2021-06-30 | $83 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2021-01-01 to 2021-06-30 | $333 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-04-01 to 2021-06-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2021-01-01 to 2021-06-30 | −$3.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2021-01-01 to 2021-06-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-04-01 to 2021-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2021-01-01 to 2021-06-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-04-01 to 2021-06-30 | 69,220,795 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2021-01-01 to 2021-06-30 | 68,286,033 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2021-01-01 to 2021-06-30 | −$2.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2021-01-01 to 2021-06-30 | $13.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-06-30 | $16.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-06-30 | $20.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-06-30 | $21.1m | us-gaap:Assets |
| Current liabilities | at 2021-06-30 | $2.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-06-30 | $3.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2021-06-30 | $17.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 23,654 characters.

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements contained in this report and in connection with management's discussion and analysis and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission, or SEC, on March 31, 2021. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

### OVERVIEW

Our common stock was listed on the NYSE American on June 1, 2015 and trades under the symbol “MLSS”. We have developed a proprietary, computer-controlled anesthetic delivery instrument, using The Wand, a single use disposable handpiece. The instrument is marketed in the dental sector under the trademark *CompuDent®*, and STA Single Tooth Anesthesia System, and in the medical sector under the trademark CompuMed. CompuDent is suitable for all dental procedures that require local anesthetic. CompuMed is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics, and several other disciplines. The dental instruments are sold in the United States, U.S. territories, Canada, and in over 60 other countries abroad. In June 2017, the FDA approved our 510(k) applications for marketing clearance in the United States of our CompuFlo Epidural Computer Controlled Anesthesia System. We are in the process of meeting with medical facilities and device distributors within the United States and Europe. To date there have been twelve medical devices sold in the United States and limited amounts sold internationally. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.

Milestone Scientific remains focused on advancing efforts to achieve the following four primary objectives:

- Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;
- Following obtaining successful FDA clearance of our first medical device, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company;
- Expanding our global footprint of our CompuFlo Epidural and CathCheck System by utilizing a direct field sales force and partnering with distribution companies worldwide; and
- Continuing the development of our proprietary cosmetic injection device for delivery of botulinum toxin (such as Botox® and Dysport®).

### Wand/STA Dental Market

Since its market introduction in early 2007, the Wand/STA Instrument and prior C-CLAD devices have been used to deliver over 80 million safe, effective, and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (“Henry Schein”). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. In December 2020, the exclusive distribution arrangement with Henry Schein was replaced with a non-exclusive distribution arrangement, for distribution in the United States and Canada.

In January 2021, the Company began a process of signing non-exclusive dental distribution arrangements with dental distributors in specific geographical locations in the United States and Canada. To date there are eight new non-exclusive dental distributors engaged in the USA and Canada. The goal is to add an additional non-exclusive distributor in three main cities in the USA.

The goal of changing our marketing plan from a sole exclusive distributor in the USA and Canada, to a large number of non-exclusive distributors is to increase placement of our Wand/STA instrument and thus the expansion of our dental disposables.

On the global front, we have granted exclusive marketing and distribution rights for the Wand/STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America, and Europe. They include FM Produkty Dla Stomatologii in Poland and Unident AB in the countries of Denmark, Sweden, Norway, and Iceland. Additionally, the Company is in the process of evaluating current international distributors and adding new distributors, globally as required based on the economics of the region.

### Medical Market

During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System. In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections. Milestone Scientific is in the process of meeting with medical device distributors within the United States and foreign markets. Milestone Scientific’s immediate focus is on marketing its epidural device throughout the United States and Europe.

In December 2016, we received notification from the FDA that based upon the 510(k)-application submitted for intra-articular injections, we did not adequately document that the device met the equivalency standard required for 510(k) clearances. Following consultation with the FDA Office of Device Evaluation, we intended to file a new 510(k) application for the device in 2019, however, due to financing constraints, a new 510(k) application was not filed in 2019. As of June 30, 2021, the Company has decided not to proceed with securing FDA approval for the intra-articular instrument at this time.

On April 21, 2020, Milestone Scientific, announced that it has validated and integrated the new CathCheck™ feature into the CompuFlo® Epidural System. Using CathCheck, physicians and nurses can now monitor the placement of a catheter to determine the presence or absence of a pulsatile waveform (heartbeat) providing new information that can be used to determine if the catheter is in place or has become dislodged from the epidural space. This can be performed within seconds by measuring the pulsatile waveform within the epidural space.

On October 13, 2020, Milestone Scientific announced a Group Purchasing Agreement with Premier Inc., a leading healthcare improvement company. The Agreement, which became effective November 1, 2020, allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the CompuFlo Epidural System and CathCheck. This agreement expires on February 28, 2022.

### COVID-19 Pandemic

The COVID-19 pandemic materially adversely affected the Company’s financial results and business operations. Demand for the Company’s products decreased, notably in our dental division, during the last fiscal year and only began to increase during the first quarter of 2021. However, such increased demand may or may not continue and/or demand may or may not increase from historical levels depending on the duration and severity of the COVID-19 pandemic, the effectiveness of the on-going vaccination process, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages, delivery delays, and reduced sales and operations, any of which could materially affect our business, financial condition, and results of operations.

The Company’s employees have been and are being affected by the COVID-19 pandemic. The majority of our office and management personnel are working remotely. The health of the Company’s workforce is of primary concern and the Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire Company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, the Company’s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company prior to the pandemic may be elevated. The COVID-19 pandemic is affecting the Company’s customers, suppliers, vendors, and other business partners, but the Company is not able to predict the ultimate consequences that will result therefrom.

All of these factors may have far reaching impacts on the Company’s business, operations, and financial results and conditions, directly and indirectly, including without limitation impacts on the health of the Company’s management.

Due to the above circumstances and as described generally in this Form 10-Q, the Company’s results of operations for the three and six month period ended June 30, 2021 are not necessarily indicative of the results to be expected for the full fiscal year.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category:

| Domestic-US | Three Months Ended June 30, 2021 | 2020 | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: | ---: | ---: |
| Instruments | $178,752 | $- | $354,768 | $525 |
| Handpieces | 802,916 | 38,812 | 1,606,050 | 635,490 |
| Accessories | 18,974 | 1,542 | 36,882 | 21,590 |
| Total Domestic US | $1,000,642 | $40,354 | $1,997,700 | $657,605 |
| International ROW |  |  |  |  |
| Instruments | $172,088 | $31,800 | $597,841 | $281,904 |
| Handpieces | 715,124 | 87,632 | 1,689,459 | 1,018,123 |
| Accessories | 12,548 | 7,888 | 33,109 | 21,428 |
| Total International-ROW | $899,761 | $127,320 | $2,320,409 | $1,321,455 |
| International-China |  |  |  |  |
| Instruments | $78,000 | $- | $228,000 | $- |
| Handpieces | 447,336 | - | 804,336 | - |
| Accessories | - | - | - | - |
| Total International | $525,336 | $- | $1,032,336 | $- |
| Total Product Sales | $2,425,738 | $167,674 | $5,350,445 | $1,979,060 |

### Current Product Platform

See Note 1, “Organization and Business”.

### Results of Operations

The following table sets forth the consolidated results of operations for the three months ended June 30, 2021 and 2020, respectively. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | Three Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Product sales, net | $2,425,738 | $167,674 |
| Cost of products sold | 1,056,384 | 55,626 |
| Gross profit | 1,369,354 | 112,048 |
| Operating expenses: |  |  |
| Selling, general and administrative expenses | 4,011,672 | 3,155,630 |
| Research and development expenses | 14,834 | 108,170 |
| Depreciation and amortization expense | 215,420 | 21,138 |
| Loss from operations | (2,872,572) | (3,172,890) |
| Other income, and loss on earning net | (100,401) | (5,312) |
| Gain on debt extinguishment-PPP | 276,180 | - |
| Net loss | (2,696,793) | (3,178,202) |
| Net loss attributable to noncontrolling interests | (16,325) | (11,738) |
| Net loss attributable to Milestone Scientific Inc. | $(2,680,468) | $(3,166,464) |

The following table sets forth the consolidated results of operations for the six months ended June 30, 2021 and 2020, respectively. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | Six Months Ended June 30, 2021 | 2020 |
| --- | ---: | ---: |
| Product sales, net | $5,350,445 | $1,979,060 |
| Cost of products sold | 2,178,797 | 615,326 |
| Gross profit | 3,171,648 | 1,363,734 |
| Operating expenses: |  |  |
| Selling, general and administrative expenses | 6,760,969 | 5,875,123 |
| Research and development expenses | 35,760 | 215,650 |
| Depreciation and amortization expense | 231,864 | 54,457 |
| Loss from operations | (3,856,944) | (4,781,496) |
| Other income, and loss on earning net | (101,885) | (9,659) |
| Gain on debt extinguishment-PPP | 276,180 | - |
| Net loss | (3,682,650) | (4,791,155) |
| Net loss attributable to noncontrolling interests | 29,313 | 24,476 |
| Net loss attributable to Milestone Scientific Inc. | $(3,653,336) | $(4,766,679) |

| Cash flow: | June 30, 2021 | June 30, 2020 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(2,070,310) | $(4,111,504) |
| Net cash used in investing activities | $(13,075) | $(15,499) |
| Net cash provided by financing activities | $3,836,798 | $19,220,948 |

29

### Three months ended June 30, 2021 compared to three months ended June 30, 2020

### Net sales for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $2,404,738 | $165,674 | $2,239,064 |
| Medical | 21,000 | 2,000 | 19,000 |
| **Total sales, net** | $2,425,738 | $167,674 | $2,258,064 |

Consolidated revenue for the three months ended, June 30, 2021 and 2020 were approximately $2.4 million and $168,000, respectively. Dental revenue increased approximately $2.3 million for the three months ending June 30, 2021 as compared to the three months ended June 30, 2020, due to re-opening of dental offices throughout the country, and the rest of the world, including China. Medical revenue increased approximately $19,000 for the three months ending June 30, 2021 as compared to the three months ending June 30, 2020 due to the Company attending introductory meetings with medical device distributors within the United States and European markets. The Company recorded an allowance against revenue and accounts receivable, related party of $270,864 for the quarter ended June 30, 2021.

### Gross Profit for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $1,358,226 | $111,285 | $1,246,941 |
| Medical | 11,128 | 763 | 10,365 |
| **Total gross profit** | $1,369,354 | $112,048 | $1,257,306 |

Consolidated gross profit for the three months ended June 30, 2021 and 2020 were approximately 56% and 67%, respectively.

### Selling, general and administrative expenses 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $648,170 | $758,394 | $(110,224) |
| Medical | 1,113,918 | 706,427 | $407,491 |
| Corporate | 2,249,584 | 1,690,809 | $558,775 |
| **Total selling, general and administrative expenses** | $4,011,672 | $3,155,630 | $856,042 |

Consolidated selling, general and administrative expenses for the three months ended June 30, 2021 and 2020, were approximately $4 million and 3.1 million respectively. The increase of approximately $856,000 is categorized in several areas. Employee salaries, and benefits expenses increased approximately $152,000 during the three months ended June 30, 2021, as the Company hired additional employees to work on the commercialization of the *CompuFl*o® Epidural System. During the three months ended June 30, 2021, royalties, employee travel and marketing expenses increased approximately $187,000 due to the re-opening of dental, and medical offices throughout the country, and the rest of the world. During the three months ended June 30, 2021, the Company expensed board fees of approximately $643,000 and issued 267,980 shares of restricted stock to the board of directors for services provided over the next year. The Company's trade shows, professional fees, quality control, and general expenses decreased approximately $304,000 during for three months ended June 30, 2021.

### Research and Development for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $184,376 | $- | $184,376 |
| Medical | 31,044 | 108,144 | (77,100) |
| Corporate | - | - | - |
| **Total research and development** | $215,420 | $108,144 | $107,276 |

Consolidated research and development expenses for the three months ended, June 30, 2021 and 2020, were approximately $215,000 and $108,000, respectively. The increase of approximately $107,000 is related to the Company exploring possible development of our proprietary STA Single Tooth Anesthesia System.

### Profit (Loss) from Operations for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase Decrease |
| --- | ---: | ---: | ---: |
| Dental | $524,798 | $(650,236) | $1,175,034 |
| Medical | (1,135,001) | (814,429) | (320,572) |
| Corporate | (2,262,369) | (1,708,225) | (554,144) |
| Total loss from operations | $(2,872,572) | $(3,172,890) | $300,318 |

The loss from operations was approximately $2.9 million and $3.2 million for the three months ending June 30, 2021 and 2020, respectively. The decrease is the result of increased in dental revenue, due to re-opening of dental offices throughout the country, the rest of the world, and China, and increase in selling, general and administrative expenses as discussed above.

### Six months ended June 30, 2021 compared to six months ended June 30, 2020

### Net sales for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $5,258,395 | $1,969,260 | $3,289,135 |
| Medical | 92,050 | 9,800 | 82,250 |
| **Total sales, net** | $5,350,445 | $1,979,060 | $3,371,385 |

Consolidated revenue for the six months ended, June 30, 2021 and 2020 were approximately $5.3 million and $2.0 million, respectively. Dental revenue increased approximately $3.4 million for the six months ending June 30, 2021 as compared to the six months ended June 30, 2020, due to re-opening of dental offices throughout the country, and the rest of the world, including China. Medical revenue increased approximately $82,000 for the six months ending June 30, 2021 as compared to the six months ending June 30, 2020 due to the Company attending introductory meetings with medical device distributors within the United States and European markets. The Company recorded an allowance against revenue and accounts receivable, related party of $270,864 for the quarter ended June 30, 2021.

### Gross Profit for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $3,117,908 | $1,358,680 | $1,759,228 |
| Medical | 53,740 | 5,054 | 48,686 |
| **Total gross profit** | $3,171,648 | $1,363,734 | $1,807,914 |

Consolidated gross profit for the six months ended June 30, 2021 and 2020 approximately 61% and 71%, respectively. The decreased in the gross profit is due to the lower margin in sales to China.

### Selling, general and administrative expenses 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $1,280,110 | $1,573,710 | $(293,601) |
| Medical | 2,031,956 | 1,273,238 | 758,718 |
| Corporate | 3,448,903 | 3,028,175 | 420,728 |
| **Total selling, general and administrative expenses** | $6,760,969 | $5,875,123 | $885,845 |

Consolidated selling, general and administrative expenses for the six months ended June 30, 2021 and 2020, were approximately $6.8 million and 5.9 million, respectively. The increase of approximately $885,000 is categorized in several areas. Employee salaries, and benefits expenses increased approximately $568,000 during the six months ended June 30, 2021, as the Company hired additional employees to work on the commercialization of the *CompuFl*o® Epidural System. During the six months ended June 30, 2021, the Company expensed board fees of approximately $643,000 and issued 267,980 shares of restricted stock to the board of directors for services provided over the next year.

During the sixmonths ended June 30, 2021, royalties, and marketing expenses increased approximately $246,000 due to the re-opening of dental, and medical offices throughout the country, and the rest of the world. The Company's trade shows, professional fees, quality control, and general expenses decreased approximately $782,000 marketing for three months ended June 30, 2021.

### Research and Development for 2021 and 2020 were as follows:

|  | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Dental | $184,376 | $- | $184,376 |
| Medical | 47,488 | 215,650 | (168,162) |
| Corporate | - | - | - |
| **Total research and development** | $231,864 | $215,650 | $16,214 |

Consolidated research and development expenses for the six months ended, June 30, 2021 and 2020, were approximately $23,000 and $215,000, respectively. The increase of approximately $16,000 is related to the Company exploring possible development of our proprietary STA Single Tooth Anesthesia System.

### Profit (Loss) from Operations for 2021 and 2020 were as follows:

| Dental | 2021 | 2020 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Medical | $1,650,831 | $(223,856) | $1,874,688 |
| Corporate | (2,030,720) | (1,484,241) | (546,479) |
| Total loss from operations | (3,477,056) | (3,073,399) | (403,657) |
|  | $(3,856,945) | $(4,781,496) | $924,552 |

The loss from operations was approximately $3.9 million and $4.7 million for the six months ending June 30, 2021 and 2020, respectively. The decrease is the result of increased in dental revenue, due to re-opening of dental offices throughout the country, the rest of the world, and China, and increase in selling, general and administrative expenses as discussed above.

### Liquidity and Capital Resources

On June 30, 2021, Milestone Scientific had cash and cash equivalents of approximately $16.0 million and working capital of approximately $17.2 million versus working capital of $15.7 million on December 31, 2020. For the six months ended June 30, 2021 and 2020, we had cash flows used in operating activities of approximately $2.1 million.

In the second quarter of 2020 the Company completed two capital raises. In April 2020, the Company completed a Common Stock offering generating gross proceeds of approximately $5.1 million (5,420,000 common shares and 2,710,000 warrants). The combined price of the shares and warrants was $0.95 per share. The warrants are exercisable at a price of $1.20 per share and have an expiration of three years from the issue date. In June 2020, the Company completed a second Common Stock offering generating gross proceeds of approximately $14.6 million (6,770,000 common shares and 3,749,000 warrants). The combined price of shares and warrants of was $2.15 per share. The warrants are exercisable at a of $2.60 and expire three years from the issue date (see Note 9). With the combination of these two Common Stock offerings, the Company has sufficient liquidity to support operations for at least a year after the date the unaudited condensed consolidated financial statements are issued.

## Market risk

As filed, 162 characters.

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

## Controls and procedures

As filed, 1,187 characters.

Milestone Scientific’s Chief Executive Officer has evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Chief Executive Officer has concluded that the disclosure controls and procedures as of June 30, 2021 are effective to ensure that information required to be disclosed in the reports

Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Chief Executive Officer, to allow timely decisions regarding required disclosure.

There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

## Risk factors

As filed, 4,100 characters.

**The COVID-19 pandemic has and may continue to adversely affect the Company’s business. Additional factors could exacerbate such negative consequences and/or cause other materially adverse effects.**

The COVID-19 pandemic did materially adversely affect the Company’s financial results and business operations in the Company’s fiscal year ended December 31, 2020, while economic and health conditions in the United States and across most of the globe have continued to change rapidly since the end of 2020. In the short-term, demand for the Company’s dental products is showing an increase in sell through activity to dental offices. However the change in demand may or may not continue and/or demand may or may not increase from historical levels depending on the duration and severity of the COVID-19 pandemic, the effectiveness of the ongoing vaccination process, the length of time it takes for normal economic and operating conditions to resume, additional governmental actions that may be taken and/or extensions of time for restrictions that have been imposed to date, and numerous other uncertainties. Such events may result in business and manufacturing disruption, inventory shortages, delivery delays, and reduced sales and operations, any of which could materially affect our business, financial condition, and results of operations.

**The ability of the Company’s employees to work may be significantly impacted by the Coronavirus.**

The Company’s employees are being affected by the COVID-19 pandemic. The majority of our office and management personnel are working remotely. The health of the Company’s workforce is of primary concern and the Company may need to enact further precautionary measures to help minimize the risk of our employees being exposed to the coronavirus. Further, our management team is focused on mitigating the adverse effects of the COVID-19 pandemic, which has required and will continue to require a large investment of time and resources across the entire Company, thereby diverting their attention from other priorities that existed prior to the outbreak of the pandemic. If these conditions worsen, or last for an extended period of time, the Company’s ability to manage its business may be impaired, and operational risks, cybersecurity risks and other risks facing the Company even prior to the pandemic may be elevated.

The COVID-19 pandemic is affecting the Company’s customers, suppliers, vendors, and other business partners, but the Company is not able to assess the full extent of the current impact nor predict the ultimate consequences that will result therefrom.

**The full effects of the COVID-19 pandemic are highly uncertain and cannot be predicted.**

The COVID-19 pandemic affected the Company’s operations in the fiscal year ended December 31, 2020 and may continue to do so for an indeterminable period thereafter. All of these factors may have far reaching impacts on the Company’s business, operations, and financial results and conditions, directly and indirectly, including without limitation impacts on the health of the Company’s management and employees, manufacturing, distribution, marketing, sales operations, customer, and consumer behaviors, and on the overall economy. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Form 10-Q, the Company’s results of operations for the three-month period ended March 31, 2021 are not necessarily indicative of the results to be expected for the full fiscal year. Management cannot predict the continued impact of the COVID-19 pandemic on the Company’s sales channels, supply chain, manufacturing, and distribution nor to economic conditions generally, including the effects on consumer spending. The ultimate extent of the effects of the COVID-19 pandemic on the Company is highly uncertain and will depend on future developments, and such effects could exist for an extended period of time even after the pandemic might end.

Filed Aug 13, 2021.
Source: SEC EDGAR, the filing index for accession 0001437749-21-019885. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
